Poolbeg Pharma PLC Upcoming events participation
21 October 2022 - 5:00PM
RNS Non-Regulatory
TIDMPOLB
Poolbeg Pharma PLC
21 October 2022
Poolbeg Pharma plc
Upcoming Events
21 October 2022 - Poolbeg Pharma (AIM: POLB, OTCQB: POLBF), a
clinical stage infectious disease pharmaceutical company with a
capital light clinical model, announces that its management and
business development team will be attending and presenting at a
number upcoming partnering and investor events from October 2022 to
January 2023.
Partnering events
-- BIO-Europe from 24-26 October 2022 at Leipzig Messe, Leipzig,
Germany 04356
-- Jefferies London Healthcare Conference from 15-17 November 2022
in London
-- JP Morgan 41(st) Annual Healthcare Conference from 9-12 January
2023 at the Westin St. Francis Hotel, San Francisco, CA
Investor events
-- London South East Webinar (virtual) on 8 November 2022. Register
here
-- LSX InvEUR$tival Showcase(TM) on 14 November 2022 at Old Billingsgate,
London EC3R 6DX. Poolbeg CEO, Jeremy Skillington, will present
at 14:15 on Stage 4: Biotech Late Growth. Register here
Event details may be subject to change - further information and
updates are available on the Poolbeg Pharma website here .
- Ends -
Enquiries
Poolbeg Pharma Plc
Jeremy Skillington, CEO +44 (0) 20 7183
Ian O'Connell, CFO 1499
finnCap Ltd (Nominated Adviser & Joint
Broker)
Geoff Nash, James Thompson, Charlie
Beeson
Nigel Birks, Harriet Ward (ECM) +44 (0) 20 7220 0500
Singer Capital Markets (Joint Broker)
Phil Davies, Sam Butcher +44 (0) 20 7496 3000
J&E Davy (Joint Broker)
Anthony Farrell, Niall Gilchrist +353 (0) 1 679 6363
Instinctif Partners +44 (0) 20 7457 2020
Melanie Toyne Sewell, Rozi Morris, poolbeg@instinctif.com
Tim Field
About Poolbeg Pharma
Poolbeg Pharma is a clinical stage infectious disease
pharmaceutical company, with a unique capital light clinical model
which aims to develop multiple products faster and more cost
effectively than the conventional biotech model. The Company,
headquartered in London, is led by a team with a track record of
creation and delivery of shareholder value and aspires to become a
"one-stop shop" for pharma and biotech seeking mid-stage products
to license or acquire.
The Company is targeting the growing infectious disease market.
In the wake of the COVID-19 pandemic, infectious disease has become
one of the fastest growing pharma markets and is expected to exceed
$250bn by 2025.
With its initial assets from Open Orphan plc , an industry
leading infectious disease and human challenge trials business,
Poolbeg has access to knowledge, experience, and clinical data from
over 20 years of human challenge trials. The Company is using these
insights to acquire new assets as well as reposition clinical stage
products, reducing spend and risk. Amongst its portfolio of
exciting assets, Poolbeg has a small molecule immunomodulator for
severe influenza (POLB 001) which has commenced its LPS human
challenge trial with initial results expected by year end 2022; a
first-in-class, intranasally administered RNA-based immunotherapy
for respiratory virus infections (POLB 002); and a vaccine
candidate for Melioidosis (POLB 003). The Company is also
developing an oral vaccine delivery platform and is progressing two
artificial intelligence (AI) programmes to accelerate the power of
its human challenge model data and biobank, with results from the
first programme expected by year end 2022.
For more information, please go to www.poolbegpharma.com or
follow us on Twitter and LinkedIn @PoolbegPharma.
This information is provided by Reach, the non-regulatory press
release distribution service of RNS, part of the London Stock
Exchange. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
Reach is a non-regulatory news service. By using this service an
issuer is confirming that the information contained within this
announcement is of a non-regulatory nature. Reach announcements are
identified with an orange label and the word "Reach" in the source
column of the News Explorer pages of London Stock Exchange's
website so that they are distinguished from the RNS UK regulatory
service. Other vendors subscribing for Reach press releases may use
a different method to distinguish Reach announcements from UK
regulatory news.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NRADZMZGNGRGZZM
(END) Dow Jones Newswires
October 21, 2022 02:00 ET (06:00 GMT)
Poolbeg Pharma (LSE:POLB)
Historical Stock Chart
From Jun 2024 to Jul 2024
Poolbeg Pharma (LSE:POLB)
Historical Stock Chart
From Jul 2023 to Jul 2024